Back

Quantifying the impact of real-world evidence: the sacubitril/valsartan experience

31 August 2025 (12:15 - 13:00)
Organised by: Logo
Congress Presentation Part of: Epidemiology, prognosis, and outcome in chronic heart failure (3) Epidemiology, Prognosis, Outcome ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Doctor Saif Rathore

Sandbar Life Sciences, Kankakee (United States of America)

3 More presentations in this session

Presentation thumbnail
In patients with heart failure with unplanned admission to hospital lack of improvement in quality-of-life 2 months after discharge identifies individuals at very high risk of readmission or death.
Mrs M. Mcginlay (Leeds, GB)
Abstract Slides Video
Presentation thumbnail
Impact of severe mitral regurgitation on patients with 'De Novo' heart failure and reduced ejection fraction: baseline characteristics and survival analysis
Mr M. Mejuto Blanco (Santiago de Compostela, ES)
Abstract Slides Video
Presentation thumbnail
Heart rate control in heart failure: insights from nationwide multicenter registry HEROES.
Professor J. Kasprzak (Lodz, PL)
Abstract Slides Video

Access the full session

Session thumbnail
Epidemiology, prognosis, and outcome in chronic heart failure (3)

The Event

Event poster

ESC Congress 2025

31 August 2025 12:15 CET
You may be interested in
thumbnail
Congress Presentation
Real-world evidence or real-world reality - Is Real world evidence a mirror or magnifier of RCTs?
thumbnail
Congress Presentation
Improvements in medical therapy and prognosis for patients with HFrEF following the 2021 ESC HF Guidelines: a nationwide registry study
thumbnail
Congress Presentation
A value-based analysis of the systematic use of dapagliflozin in patients with heart failure

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources